» Articles » PMID: 29080397

Astatine

Overview
Date 2017 Oct 29
PMID 29080397
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

This educational review describes and summarizes the historic discovery of element 85, the experiments leading to its physical and chemical characterization and comparison with its lighter homologue iodine. The half-lives of its longest living isotopes At and At with 8.3 and 7.22 hours respectively together with their alpha decay characteristics made these isotopes interesting for radiation biological research. However, the lack of stable isotopes of astatine presents a strong challenge for all characterizations. Nevertheless, the decay characteristics especially of At stimulated several research groups to develop labelling strategies for the preparation of astatinated radiopharmaceuticals for targeted alpha radiation therapy. Because of the distinct differences in the chemical behaviour of astatine, when compared with iodine, these approaches are quite challenging. Accordingly, quite different labelling strategies have been tested, namely nucleophilic and electrophilic substitution reactions as well as complex forming strategies. Classic and new developments for the preparation of these compounds are reviewed.

Citing Articles

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211.

Timperanza C, Jensen H, Back T, Lindegren S, Aneheim E Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111352 PMC: 10145095. DOI: 10.3390/ph16040595.


Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter.

Tutov A, Chen X, Werner R, Muhlig S, Zimmermann T, Nose N Pharmaceutics. 2023; 15(2).

PMID: 36840011 PMC: 9963373. DOI: 10.3390/pharmaceutics15020690.


Covalent core-radiolabeling of polymeric micelles with I/At for theranostic radiotherapy.

Sporer E, Poulie C, Back T, Lindegren S, Jensen H, Kempen P Nanotheranostics. 2022; 6(4):388-399.

PMID: 35912139 PMC: 9330252. DOI: 10.7150/ntno.71906.


Gold Nanostars: A Novel Platform for Developing At-Labeled Agents for Targeted Alpha-Particle Therapy.

Liu Y, Zhou Z, Feng Y, Zhao X, Vaidyanathan G, Zalutsky M Int J Nanomedicine. 2021; 16:7297-7305.

PMID: 34737567 PMC: 8560129. DOI: 10.2147/IJN.S327577.


An expanded halogen bonding scale using astatine.

Liu L, Rahali S, Maurice R, Gomez Pech C, Montavon G, Le Questel J Chem Sci. 2021; 12(32):10855-10861.

PMID: 34447565 PMC: 8372311. DOI: 10.1039/d1sc02133h.